Sign in to view content

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD

Peter A. Campochiaro, MD

Video
Published 2020

Related

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Impact of Retinal Ischemia on Visual Acuity Outcomes
Michael Peter Fielden, MD, FRCS(C)
Updates from the Field
2016
Episode 14: Plasma VEGF Levels After Anti-VEGF Injections (DRCR protocol T) with Dr. Charles Wykoff
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more